Surviving Breast Cancer
Tens of thousands of women have breast cancer that comes back.54-year-old Cynthia Tyng is a gallery manager from Old City, who is dealing with recurring cancer.Tyng was first diagnosed with breast cancer in ...Comment
topix.net 3h and 28m ago
Most women 'go off tamoxifen too soon'
About one third of women with breast cancer who are being treated with tamoxifen stop taking the medication before the end of the recommended five years of therapy, a study shows.Comment
topix.net 5h and 4m ago
Elizabeth Edwards' metastasized breast cancer should be treatable
The recurrence of Elizabeth Edwards' breast cancer years after treatment is a serious setback, but probably one she can live with for five to 10 years, perhaps even longer, experts said Thursday.Comment
topix.net 21h and 24m ago
Edwards Will Continue Presidential Run
John Edwards said Thursday that his wife is now battling an incurable reappearance of cancer but vowed to continue his second bid for the Democratic presidential nomination.Comment
topix.net Thu, 22 Mar 2007 16:51:12 GMT
Chemosensitive P53-Mutant Breast Cancers
Hugues de The and colleagues report that TP53 status is a predictive factor for responsiveness in breast cancers to a dose-dense epirubicin-cyclophosphamide chemotherapy regimen, and suggests that this regimen might be well suited for patients with TP53 mutant tumors.###Everything published by PLoS Medicine is Open Access: freely available for anyone to read, download, redistribute and otherwise use, as long as the authorship is properly attributed.
Medicalnewstoday.com Thu, 22 Mar 2007 08:00:00 PDT
Potential 'Smart' Therapies For Breast, Ovarian Cancer from UBC Discovery
New non-toxic and targeted therapies for metastatic breast and ovarian cancers may now be possible, thanks to a discovery by a team of researchers at the University of British Columbia.
Medicalnewstoday.com Wed, 21 Mar 2007 11:00:00 PDT
Plant Estrogen May Cut Breast Cancer
Title: Plant Estrogen May Cut Breast CancerCategory: Health NewsCreated: 3/21/2007Last Editorial Review: 3/21/2007
medicinenet.com Wed, 21 Mar 2007 00:00:00 PDT
High-Fat Diet Linked to Breast Cancer
Title: High-Fat Diet Linked to Breast CancerCategory: Health NewsCreated: 3/21/2007Last Editorial Review: 3/21/2007
medicinenet.com Wed, 21 Mar 2007 00:00:00 PDT
Racial Disparities Seen In Male Breast Cancer Survival
A new study shows that among men treated for breast cancer, African-American men are more likely to die of the disease compared with white men. The results of the study are published online in the Journal of Clinical Oncology (JCO).The studies by researchers at Columbia University analyzed race and other predictors of treatment and survival among 510 men over 65 diagnosed with stage I-III breast cancer between 1991 and 2002.
Medicalnewstoday.com Tue, 20 Mar 2007 23:00:00 PDT
Discovery May Lead To New Cancer Therapies
VANCOUVER, British Columbia -- Canadian researchers have made a discovery that might lead to new non-toxic, targeted therapies for metastatic breast and ovarian cancers. The researchers at the University of British Columbia found a protein called podocalyxin -- which had previously shown to be a predictor of metastatic breast cancer -- changes the shape and adhesive quality of tumor cells, affecting their ability to grow and metastasize. The discovery demonstrates the protein not only predicts the spread of breast cancer cells, it likely helps cause it. "We believe we've found a new important culprit in metastatic breast cancer, which opens up an entirely new avenue of cancer research," said Calvin Roskelley, an ass...
cancercompass.com Mon, 19 Mar 2007 00:00:00 CDT
Breast Cancer Treatment Heats Up
RESTON, Va. -- In this month's Journal of Nuclear Medicine, researchers demonstrate that miniscule bioprobes could be produced and used with molecularly targeted therapeutic heat to kill malignant breast cancer cells -- without damaging nearby healthy tissue. While many researchers have studied using heat in treating cancer, "the inability to deposit effective doses of heat in a tumor without applying similar heat to nearby normal tissue has prevented widespread clinical use," said Sally J. De Nardo, professor of internal medicine and radiology with the School of Medicine at the University of California Davis in Sacramento. "Our animal study, which combined the future-oriented sciences of nanotechnology and molecular imaging,...
cancercompass.com Mon, 19 Mar 2007 00:00:00 CDT
Scouting For The Cure: Girl Scouts Take Part In Fight To Defeat Breast Cancer
Thanks to Margaret Stothart and Neel Stallings -- two sisters who are breast cancer survivors -- thousands of Charlotte, N.C. area Girl Scouts and their leaders will be Scouting for the Cure this weekend. Saturday's three-hour event at Rama Road Elementary School will arm the Scouts with the latest information about breast cancer, giving the girls a head start on their own breast health. Statistics show the girls also will save the lives of at least a few moms or grandmothers who will begin self-exams or have mammograms as a result of their Scout's encouragement. Stothart had a daughter, Elizabeth, when she was in her early 40s, and was diagnosed with breast cancer at age 47. "I had this little 4-year-old climbing in my lap tryi...
cancercompass.com Mon, 19 Mar 2007 00:00:00 CDT
Recent Findings In Breast Cancer Therapy Described By Researchers From All India Institute Of Medical Sciences
New research, "Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients," is the subject of a report. In this recent study, researchers in New Delhi, India conducted a study "To evaluate the results of radiofrequency ablation in treating hepatic metastases from breast cancer. Fourteen breast cancer patients with 16 hepatic metastases measuring 1.1 to 4.0 cm in the longest axis (mean, 1.9 cm) were prospectively studied. All patients had previously received chemotherapy." "Radiofrequency ablation was done using 17-G, internally cooled electrodes under ultrasound guidance. A single index tumor was treated in 12 patients, and two tumors each were treated in two patients. Follow-up was done using serial computed...
cancercompass.com Mon, 19 Mar 2007 00:00:00 CDT
FDA Approves Tykerb® (Lapatinib) In Combination With Xeloda® (Capecitabine) For The Treatment Of Advanced Or Metastatic Breast Cancer
GlaxoSmithKline plc [NYSE: GSK, LSE: GSK] announced today that the United States Food and Drug Administration (FDA) approved TYKERB® (lapatinib), in combination with Xeloda® (capecitabine), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. It is the first targeted, once-daily oral treatment option for this patient population.
Medicalnewstoday.com Mon, 19 Mar 2007 00:00:00 PDT
Diet and Nutrition: The Dangers of Barbecued Meat
Title: Diet and Nutrition: The Dangers of Barbecued MeatCategory: Ask The ExpertsCreated: 3/19/2007Last Editorial Review: 3/19/2007
medicinenet.com Mon, 19 Mar 2007 00:00:00 PDT
FDA Approves New Breast Cancer Drug
Title: FDA Approves New Breast Cancer DrugCategory: Health NewsCreated: 3/14/2007Last Editorial Review: 3/14/2007
medicinenet.com Wed, 14 Mar 2007 00:00:00 PDT
NHS blames Kylie for cancer target failures
THE "Kylie effect" is to blame for the NHS's failure to meet waiting time targets for breast cancer, say health service officials.
Scotsman Thu, 08 Mar 2007 01:37:30 GMT
Poor lose out in breast cancer treatment
WOMEN from deprived areas receive worse treatment for breast cancer than those living in more affluent communities, according to a new study.
Scotsman Wed, 07 Mar 2007 01:35:47 GMT
Two more high-flyers sign up
TWO more businesswomen have signed up to take part in a £400,000 fundraising drive in aid of breast cancer charities.
Scotsman Tue, 06 Mar 2007 11:52:23 GMT
Elizabeth Edwards Back in the Battle, Presidential Campaign Continues
Saving Graces, by Elizabeth Edwards Broadway Books. Photographer: Deborah Feingold John and Elizabeth Edwards have announced that her breast cancer has returned and spread to a bone....
About
African-American Male Breast Cancer Survival Rates Lower
Racial Disparity for African-American Men and Women Breast Cancer PatientsA new study done with data from Surveillance Epidemiology and End Results (SEER) cancer registry shows that African-American men who were...
About
Tykerb Approved by US FDA to Fight Breast Cancer
Tykerb (lapatinib) is approved for treating HER2 positive breast cancer, for patients who cannot tolerate Herceptin (trastuzumab). Tykerb is taken orally and is used alongside chemotherapy, and has been...
About
95-year-old Breast Cancer Fighter Roars Ahead on Motorbike
If you want to do something in your life, get on with it."She's a hard act to follow," said Helen Groeber, 87-year-old sister of Elizabeth Woodhouse. That's Dr....
About
Roles for estrogen and progesterone in breast cancer prevention
Prevention has long been the holy grail of breast cancer research. The significant reduction in breast cancer risk afforded by a full-term pregnancy early in life suggests the great potential of preventive strategies. In contrast to the risks associated with prolonged exposures, exogenous estrogen and progesterone for short durations can mimic the protective effects of pregnancy in carcinogen-induced mammary tumor models. Rajkumar and coworkers have now demonstrated that these hormones protect mice from mammary tumors initiated by a spectrum of oncogenic alterations that are common in breast cancers. Although differences between rodent models and humans remain, the results reveal that exogenous estrogen and progesterone potently inhibit tumorigenesis through multiple pathways and establish a foundation for strategies to prevent breast cancer.
breast-cancer-research.com
Gata-3 and mammary cell fate
Genomic regulatory networks specify how cellular gene expression responds to external temporal and spatial stimuli, ensuring that correct cell fate decisions are made and the appropriate cell phenotypes are adopted. In mammary epithelial cells, the hierarchy of stem and progenitor cells and the genetically specified program of transcriptional activity are beginning to be elucidated and integrated. A novel role for Gata-3 in specifying and maintaining mammary cell fate has recently been identified. These reports offer an understanding of how mammary cells assume and maintain a variety of cell behaviours and functions, and how a mammary cell may potentially subvert these constraints during carcinogenesis.
breast-cancer-research.com
Association of estrogen receptor alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment
IntroductionMedroxyprogesterone acetate (MPA) induces estrogen (ER) and progesterone receptor (PR) positive ductal invasive mammary carcinomas in BALB/c mice. We sought to reproduce this MPA cancer model in C57BL/6 mice because of their widespread use in genetic engineering. Within this experimental setting we studied the carcinogenic effects of MPA, the morphological changes in the mammary glands that are induced by MPA and progesterone (Pg), as well as the levels of ER and PR expression in MPA or Pg-treated mammary glands. Finally we evaluated whether the differences found between BALB/c and C57BL/6 mouse strains were due to intrinsic differences in the epithelial cells.Methods:The carcinogenic effect of MPA was evaluated in C57BL/6 mice using protocols proven carcinogenic in BALB/c mice. In addition, BALB/c and C57BL/6 females were treated with Pg or MPA for one or two months and mammary glands excised for histological studies and for immunohistochemical and Western blot evaluation of ER and PR. Hormone levels were determined by radioimmunoassay. Isolated mammary epithelial cells were transplanted into cleared fat pads of 21 day old female Swiss nu/nu mice or control congenic animals.Results:MPA failed to induce mammary carcinomas or significant morphological changes in the mammary glands of C57BL/6 mice. The expression of ER alpha (ERa) and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands and both receptors were downregulated in progestin-treated BALB/c mice (p<0.05). PR isoform B levels were low in virgin control mice and increased after progestin treatment in both strains. ER beta (ERb) expression followed a similar trend. No differences in hormone levels were found between strains. Surprisingly, the transplantation of the epithelial mammary gland cells of both strains into the cleared fat pads of Swiss (nu/nu) mice abolished the mammary gland morphological differences and the ER and PR differences between strains.Conclusions:a) C57BL/6 mammary glands are resistant to MPA-induced carcinogenesis and to hormone action, b) MPA and Pg have different effects on mammary glands, c) low ERa and PR A levels in untreated mammary glands may be associated with a low risk breast cancer profile, d) even though we cannot at this time rule out the participation of other, untested factors, our results point to the stroma as playing a crucial role in the strain specific differential hormone receptor expression and hormone responsiveness.
breast-cancer-research.com
Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study
IntroductionDouble-peaked time distributions of the mortality hazard function have been reported for breast cancer patients from Western populations treated with mastectomy alone. These are thought to reflect accelerated tumor growth at micrometastatic sites mediated by angiogenesis after primary tumor removal as well as tumor dormancy. Similar data is not available for Asian populations. We sought to investigate if differences exist in the pattern of mortality hazard functions between Western breast cancer patients and their Asian counterparts in Singapore, which may suggest underlying differences in tumor biology between the two populations. Methods:We performed a retrospective cohort study of female unilateral breast cancer patients diagnosed in Singapore between October 1994 to June 1999. Data regarding patient demographics, tumor characteristics and death were available. Overall survival curves were calculated using the Kaplan-Meier method. The hazard rate was calculated as the conditional probability of dying in a time interval, given that the patient was alive at the beginning of the interval. The life table method was used to calculate the yearly hazard rates.Results:In the 2105 women identified, 956 patients (45.4%) had mastectomy alone. Demographics were: 86.5% Chinese; 45.2% postmenopausal; 38.9% hormone receptor positive; 54.6% node negative; 44.1% high histological grade. A double-peaked mortality hazard pattern, with a first major mortality rise reaching the maximum at the 2nd - 4th year after mastectomy and a second large mortality rise in the 9th year was observed. Analyses by subgroups showed a similar pattern regardless of T stage, nodal or menopausal status. This pattern was also noted in high-grade tumors but not in those well to moderately differentiated. The double-peaked pattern observed in Singaporean women was quantitatively and qualitatively similar to that reported by Western series. Conclusion:Our study confirms a double-peaked process in Asian patients and gives further support to the tumor dormancy hypothesis after mastectomy.
breast-cancer-research.com
Breast cancer skydive wins Jack's support
FIRST Minister Jack McConnell has lent his support to a £400,000 fundraising drive in aid of breast cancer charities.
Scotsman Tue, 27 Feb 2007 12:16:21 GMT
Switching Breast Cancer Drugs May Boost Survival (HealthDay)
Switching to newer breast cancer drugs, called aromatase inhibitors, after two to three years of treatment with tamoxifen may extend disease-free survival and slightly reduce the risk of death in women who've been treated for early stage disease, an international study finds.
yahoo.com Wed, 14 Feb 2007 04:40:42 GMT
Vitamin D Studies Show Promise for Reducing Cancers (HealthDay)
Certain amounts of vitamin D may be able to prevent up to half of breast cancer cases and two-thirds of colorectal cancer cases in the United States, according to two studies by researchers at the Moores Cancer Center at the University of California, San Diego, and colleagues at other centers.
yahoo.com Tue, 13 Feb 2007 04:40:40 GMT
Archive | 
